Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...

This document provides information about the F-Tile Avalon® Streaming IP for PCI Express Configuration Intercept Interface (CII) interface. The document details an example design that demonstrates CII ...

The Intercept dropped its most significant story in its three-year history on Tuesday. The website published a piece based on leaked NSA documents that detailed what appeared to be a previously ...

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

There were six violations of a restricted airspace over Bedminster, New Jersey, while President Donald Trump was staying at his residence there over the weekend, the U.S. Air Force said. One of those ...

Alongside the withdrawal request, the FDA has also placed a clinical hold on all Intercept clinical trials involving obeticholic acid. Intercept Pharmaceuticals has decided to voluntarily withdraw ...

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval last year after an advisory committee was unable to verify a favorable ...

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...